Review top news and interview highlights from the week ending February 10, 2023.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The updated data included a median overall survival of 26 months after treatment with brexu-cel.
The associate attending physician at Memorial Sloan Kettering Cancer Center discussed further research that remains to be conducted with the allogeneic cell therapy.
The company is developing a one-time, non-AAV2 gene replacement therapy to restore, treat, and prevent blindness of patients with RPE65 mutation-associated retinopathies.
Mehra and Subramanian discussed preclinical safety studies with the gene therapy SLS-004 and plans for future research.
The FDA cleared Century’s IND for CNTY-101 in August 2022.
Expanding Access to Whole Genome Sequencing in Parkinson Research
May 12th 2025James Beck, PhD, chief scientific officer of the Parkinson’s Foundation, discussed the foundation’s efforts to integrate whole genome sequencing into PD GENEration and expand access across diverse global populations.